Ninlaro (Ixazomib Citrate) Patent Expiration, LOE Window & CMS Spending

Ninlaro (Ixazomib Citrate) by Takeda: FDA Orange Book core substance LOE 2029-11-20, 0 AB generics, $282.6M 2024 CMS Part D & Medicaid spend, and 26 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN208462 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2029-11-20
Last Listed Patent or Exclusivity Date2029-11-20
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$282.6M
2024 Medicare Part D Spend$272.7M
2024 Medicaid Spend$9.9M
Reported Wholesale Price Change (CA SB 17)26 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.